Juventas Preps for Phase II Studies with $22M Series B
Juventas Therapeutics Inc., of Cleveland, is funded through the end Phase II trials for its biologic product, JVS-100, now that it has closed a $22.2 million Series B financing round co-led by Triathlon Medical Venture Partners and New Science Ventures.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-877-857-2477
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter